biotechnology

Two experts share the Aussie names with big catalysts on the horizon.

Forget the unicorn hunt. Outperformance lives in evidence-based asymmetry, mispriced assets, and free options the market doesn’t see.

Platinum Asset Management’s Dr Bianca Ogden and KP Rx’s Hashan de Silva share their latest investments.

Extended interview with CEO Gary Phillips

We take a look at 4 Pharma & Biotech companies whose share prices rallied in October on the back of positive announcements.

Wilsons Advisory’s Melissa Benson and Shane Storey share their insights in the final part of the biotech mini-series.

KP Rx’s Hashan De Silva thinks so and is seeing enormous opportunities at attractive valuations.

Despite a bear market, this sector has seen innovation accelerate and its fortunes are about to change.

In this episode, Nina shares her background and what it taught her about the challenge of running a biotech firm.

...according to HB Biotechnology’s Charlie Williams.